NAMOur WorkProgramsLeadership ConsortiumEvidence Mobilization Action Collaborative​

Evidence Mobilization
Action Collaborative

Supporting the conditions necessary for transforming real world experiences into valuable data that are routinely used to improve population and patient-level health

About the Evidence Mobilization Action Collaborative

As one of four action collaboratives under the National Academy of Medicine’s Leadership Consortium, the Evidence Mobilization Action Collaborative (EMAC) promotes the systematic capture of real-world health and medical experiences to improve the evidence that is used for decision-making at every level of health and health care. The EMAC aims to identify and advance best practices for generating, collecting, analyzing, and applying real-world data. 

The health system generates myriad data points in the process of monitoring, evaluating, and intervening to improve patient health. Yet, much of these data are not captured or used in ways that significantly improve the health care system or patient experiences. The EMAC aims to ensure that valuable evidence is routinely studied, strategically applied, and widely disseminated to promote a health system that can learn and improve, ultimately providing people with the health they deserve at costs they can afford.  

Co-Chairs

Medtronic

Laura Mauri, MD, MSc, is the Senior Vice President, Chief Scientific and Medical Officer at Medtronic. Laura received her A.B. from Harvard College and her M.D. from Harvard Medical School, both magna cum laude, and her M.Sc. (Clinical Epidemiology) from Harvard School of Public Health. She completed residency in internal medicine and fellowships in cardiovascular disease and interventional cardiology at the Brigham and Women’s Hospital. Laura serves on the Board of directors of (MDIC) and is a member of the NIH Advisory Committee. She is a member of the American Society of Clinical Investigation, the Association of University Cardiologists, a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and American College of Cardiology, and member of the Society of Cardiac Angiography and Intervention. She has authored approximately 200 original articles, served as a Senior Editor for the journal Circulation, and was awarded the Joseph A. Vita Award for Clinical Research by the American Heart Association in 2017.

Harvard Medical School

Richard Platt, MD, MSc is Professor and Chair of the Harvard Medical School Department of Population Medicine at the Harvard Pilgrim Health Care Institute. He is principal investigator of the FDA’s Sentinel System that studies of the safety and effectiveness of marketed medical products. Dr. Platt is also co-principal investigator of the coordinating center of PCORI’s Patient Centered Outcomes Research Institute, leads the NIH Health Care Systems Research Collaboratory’s Distributed Research Network, and is co-principal of a CDC Prevention Epicenter. He is a member of the Association of American Medical Colleges’ Advisory Panel on Research. He is a former chair of the FDA’s Drug Safety and Risk Management Advisory Committee, and co-chair of the Board of Scientific Counselors of the Centers for Disease Control and Prevention’s (CDC) Center for Infectious Diseases.

Highlander Health

Amy Abernethy, M.D., Ph.D., is cofounder of Highlander Health, an organization focused on advancing evidence generation for the new era of medical innovation. As an oncologist, serial entrepreneur, and standard setter, Dr. Abernethy is a champion for speeding the pace at which safe and effective treatments reach patients, and for progressive and responsible use of our healthcare system’s data.

Dr. Abernethy is the former principal deputy commissioner of the U.S. Food and Drug Administration. While there, Dr. Abernethy led initiatives in advancing clinical evidence generation and personalized healthcare and also served as the agency’s acting chief information officer.

More recently, Dr. Abernethy served as chief medical officer and president of product development at Verily, Alphabet’s precision health business, leading the company’s development and delivery of solutions that connect clinical research and care. Earlier roles include that of Flatiron Health’s first chief medical officer and chief scientific officer, as well as: professor of medicine at Duke University School of Medicine; director of the Center for Learning Health Care at the Duke Clinical Research Institute; and, director of the Duke Cancer Care Research Program at the Duke Cancer Institute. An avid learner and teacher, and a hematologist/oncologist and palliative medicine physician, Dr. Abernethy has authored over 500 publications.